Ge Long Hui A P P·2025-10-30 22:56Core Viewpoint - Pfizer is preparing to sue both Metsera and Novo Nordisk after Novo Nordisk outbid Pfizer for the acquisition of the obesity drug developer Metsera, which Pfizer views as a significant threat to its entry into the $150 billion obesity drug market [1] Group 1: Acquisition Details - Novo Nordisk's bid for Metsera is described as substantial but complex, utilizing a two-step transaction model that was previously rejected by Metsera's board due to high risks [1] - Pfizer claims that Novo Nordisk's proposal circumvents regulatory approval and does not meet the "superior proposal" standard [1] Group 2: Market Positioning - The acquisition of Metsera is seen as a critical move for Pfizer after it abandoned the development of oral obesity drugs, marking a pivotal moment for the company in the obesity drug market [1] - Pfizer has developed a public relations strategy positioning itself and Metsera as the "American national team," while framing Novo Nordisk's bid as a foreign "predatory acquisition" [1] Group 3: Legal and Regulatory Concerns - Pfizer emphasizes that Novo Nordisk's actions represent an illegal attempt to suppress competition by merging with an emerging American challenger, potentially violating antitrust laws [1]